Home Search
citius - search results
If you're not happy with the results, please do another search
Citius (CTXR) Announces Results of Mino-Lok Study.
"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.
2021 and 2020 Milestones In Plain Sight.
Locked and Loaded for most of 2020 - many major milestone...
Citius Pharma (CTXR) Video Presentation.
Chairman Leonard Mazur Discusses:
Mino-Lok Treatment for Infected Catheters.
Novellus Stem Cell Treatment...
Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in FDA Trials!
Great headline, right?
The actual headline was: Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
Where is Citius Pharma (CTXR) in the FDA Approval Process?
We have a number of subscribers asking for an update on the FDA approval process for Mino-Lok. In layman's term (assuming approval)...
Citius (CTXR) CEO Myron Holubiak Live on TV, 1:20 Today, June 30th.
VIDEO: Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
Citius Pharma (CTXR) On The Move.
One Of Our Top 5 Biotech Picks For 2020 Up 23% Yesterday, Indicating Up Another 24% This Morning. Inquiring Minds Want...
Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...
Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).
Citius Announces Pre-IND Submission to FDA Under the Coronavirus...
Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and Candida Auris News.
Announces Mino-lok® Erdicates the Deadly and Untreatable C. Auris Bacteria.Announces License of Treatment for CoronaVirus Respiratory Failure.
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
